ClinicalTrials.govpublic full text
Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes
anemia, myelodysplastic syndromes, refractory anemia, erythropoietin, filgrastim, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 849694
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.